Enhanced Group goes public at $1.2 billion valuation

Enhanced Group, Inc. held an IPO earlier this month at a $1.2 billion valuation. The public debut coincided with the company’s hosting of the Enhanced Games in Las Vegas, Nevada. The athletic competition featured 42 athletic contestants—including weightlifters, swimmers, and track runners—competing while using performance-enhancing drugs. To prepare for the event, the competitors spent 12 weeks in the United Arab Emirates training under medical supervision. The event featured cash incentives, including up to $1 million for breaking world records in the 100-meter sprint and 50-meter freestyle, and $250,000 for lifting a bar. During the games, Kristian Gkolomeev of Greece set a swimming record time of 20.81 seconds, breaking the previous record by a margin of 0.07 seconds. Meanwhile, Nordic bodybuilder Hafþór Björnsson failed a deadlift record attempt of 1,135.4 pounds, and Canadian weightlifter Boady Santavy failed to break the men’s snatch record of 183 kilograms, which is approximately 403 pounds.

Beyond the athletic spectacle, which drew some 200 journalists, Enhanced Group is positioning itself as a commercial distributor of human enhancement products. The company sells personalized health treatments, including peptides, testosterone injections, and weight-loss drugs, and has partnered with Rezolve Ai to launch a digital telehealth platform. According to CEO and co-founder Maximilian Martin, the peptide market in the U.S. already stands at 85 million people. Martin argues that the company provides a safe, medically supervised pathway to these substances, which are otherwise often obtained unregulated. This market could expand further depending on regulatory shifts; in July, the U.S. Food and Drug Administration (FDA) will convene a pharmaceutical advisory committee to consider loosening restrictions on certain previously banned peptides. Currently, some startups are reportedly conjuring products based on chemicals that reside in a legal gray zone.

The venture has drawn criticism from international sports and anti-doping regulators. The World Anti-Doping Agency (WADA) has called the Enhanced Games “dangerous.” Travis Tygart, the CEO of the U.S. Anti-Doping Agency (USADA), characterized the event as a “clown show that puts profit over people.” Some participating athletes, such as American swimmer Hunter Armstrong, chose to compete without using any performance-enhancing substances, citing a desire to preserve their Olympic eligibility. Despite the regulatory pushback, Enhanced Group’s leadership remains focused on the commercial opportunity. Christian Angermayer, the billionaire co-founder and executive chairman of Enhanced, defended the business model, stating: “There is no reason why something that is good should not also be a business.”

Why it matters

Enhanced Group is attempting to commercialize human enhancement through a newly public company, sparking a global debate over the safety and ethics of performance-enhancing drugs in sports and consumer health.